作者：蒋红英，程功，王依阳，赵慧，梁宸源，姜瑞嘉，任园园，陈亮，许百灵，方纬

单位：

1.710068陕西省西安市，陕西省人民医院心血管内科　2.MO65211美国密苏里州哥伦比亚市，美国密苏里哥伦比亚大学核科学暨工程研究所　3.100037北京市，中国医学科学院阜外医院核医学科

Units：

1.Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an 710068, China2.Institute of Nuclear Science and Engineering, University of Missouri Columbia, Columbia MO65211, USA3.Department of Nuclear Medicine, Fuwai Hospital, CAMS & PUMC, Beijing 100037, China

关键词：

冠状动脉疾病；冠状动脉微血管疾病；葛兰心宁；治疗结果；adropin；鸢尾素

Keywords：

Coronary artery disease; Coronary microvascular disease; Gelanxinning; Treatment outcome; adropin;Irisin

CLC：

R 541.4

DOI：

10.12114/j.issn.1008-5971.2023.00.194

Funds：

陕西省自然科学基础研究计划项目(2022JQ-891)；陕西省中医药管理局基金（2021-ZZ-ZY003）；陕西省人民医院2022年科技人才支持计划资助项目（2022LJ-04）

摘要：

目的　分析葛兰心宁治疗冠状动脉微血管疾病（CMVD）的效果及其对患者血浆adropin蛋白、鸢尾素水平的影响。方法　选取2021年7月至2022年9月陕西省人民医院收治的CMVD患者78例为研究对象。采用随机数字表法将患者分为观察组38例和对照组40例。对照组患者采用常规治疗，观察组患者在常规治疗的基础上加用葛兰心宁软胶囊，两组患者均连续治疗8周。比较两组一般资料、临床疗效、不良反应发生率及治疗前后血浆adropin蛋白、鸢尾素水平。结果　观察组临床疗效优于对照组（P＜0.05）。两组肠胃不适、恶心呕吐、过敏、出血、肝/肾功能异常发生率比较，差异无统计学意义（P＞0.05）。治疗后，两组血浆鸢尾素水平比较，差异无统计学意义（P＞0.05）；治疗后，观察组血浆adropin蛋白水平高于对照组（P＜0.05）。对照组治疗后血浆鸢尾素水平高于本组治疗前（P＜0.05）；观察组治疗后血浆adropin蛋白、鸢尾素水平高于本组治疗前（P＜0.05）。结论　葛兰心宁可有效提高CMVD患者临床疗效，且安全性好，其机制可能与葛兰心宁升高血浆adropin蛋白水平，进而发挥保护血管内皮功能的作用有关；而葛兰心宁对血浆鸢尾素水平的影响尚需要进一步研究。

Abstract：

Objective To analyse the effect of Gelanxinning on coronary microvascular disease (CMVD) and itsinfluence on plasma adropin protein and irisin levels. Methods A total of 78 CMVD patients admitted to Shaanxi ProvincialPeople's Hospital from July 2021 to September 2022 were selected as the research subjects. The patients were divided intoobservation group of 38 cases and control group of 40 cases using a random number table method. The control group receivedconventional treatment, and the observation group received Gelanxinning softgel on the basis of conventional treatment. Bothgroups received continuous treatment for 8 weeks. The general data, clinical efficacy, incidence of adverse reactions and plasmalevels of adropin protein and irisin before and after treatment were compared between the two groups. Results The clinical effectof the observation group was better than that of the control group (P < 0.05) . There was no significant difference in the incidenceof gastrointestinal discomfort, nausea and vomiting, allergy, bleeding and abnormal liver/kidney function between the two groups(P > 0.05) . After treatment, there was no significant difference in plasma irisin level between the two groups (P > 0.05) . Aftertreatment, the plasma adropin protein level in the observation group was higher than that in the control group (P < 0.05) . Thelevel of plasma irisin in the control group after treatment was higher than that before treatment (P < 0.05) . The levels of plasmaadropin protein and irisin in the observation group after treatment were higher than those before treatment (P < 0.05) . ConclusionGranxinning can effectively improve the clinical efficacy of CMVD patients and has good safety. Its mechanism may be relatedto the increase of plasma levels of apropin protein, thereby exerting a protective effect on vascular endothelial function. While the effect of Granxinning on plasma iritin levels is needed to further investigate.

ReferenceList：